APA (7th ed.) Citation

Chayab, L., Leighl, N. B., Tadrous, M., Warren, C. M., & Wong, W. W. L. Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. MDPI AG.

Chicago Style (17th ed.) Citation

Chayab, Lara, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, and William W. L. Wong. Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. MDPI AG.

MLA (9th ed.) Citation

Chayab, Lara, et al. Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. MDPI AG.